Understanding Estramustine Resistance in Prostate Cancer Cells
Author Information
Author(s): L.A. Speicher, V.R. Sheridan, A.K. Godwin, K.D. Tew
Primary Institution: Fox Chase Cancer Center
Hypothesis
The study aims to investigate the mechanisms of resistance to estramustine in human prostate carcinoma cell lines.
Conclusion
Estramustine resistance in DU 145 cells is distinct from classic multidrug resistance, showing no cross-resistance to other anti-microtubule agents.
Supporting Evidence
- EM-resistant clones did not show cross-resistance to vinblastine, taxol, or adriamycin.
- EMR lines maintained increased resistance to estramustine even after being removed from drug exposure.
- EMR clones exhibited collateral sensitivity to cytochalasin B.
Takeaway
Researchers found that some prostate cancer cells can resist a drug called estramustine, but they don't become resistant to other similar drugs, which is unusual.
Methodology
The study involved creating estramustine-resistant DU 145 cell lines through mutagenesis and assessing their resistance and sensitivity to various drugs.
Limitations
The specific mechanisms of resistance remain undefined, and the study primarily focuses on a limited number of cell lines.
Want to read the original?
Access the complete publication on the publisher's website